이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Celltrion launches autoimmune disease treatment Remsima SC in U.S.
- Collected
- 2024.03.18
- Distributed
- 2024.03.19
- Source
- Go Direct
![Zymfentra. [Courtesy of Celltrion Inc.]](https://pulsenews.co.kr///file.mk.co.kr/meet/neds/2024/03/image_readtop_2024_197042_17107267005874932.png)
이미지 확대Zymfentra. [Courtesy of Celltrion Inc.]
Remsima RC, referred to as Zymfentra in the U.S., is a product developed by converting the existing intravenous formulation of Remsima to an SC formulation that can be self-administered.
It was approved by the U.S. Food and Drug Administration (FDA) in October 2023.
The drug can be used to treat adult patients with moderate-to-severe active ulcerative colitis and Crohn‘s disease.
The wholesale price of Zymfentra has been set at approximately $6,181 for two doses based on a four-week course.
Celltrion plans to sell Zymfentra in the U.S. directly through its U.S. subsidiary. It is currently in discussion to have the product included on the preferred drug list of U.S. pharmacy benefit managers by the second quarter of this year.
Celltrion anticipates to raise more than 1 trillion won ($750.9 million) in annual sales by 2025 with the drug, targeting a prescription rate exceeding 10 percent.
Thomas Nusbickel, Chief Commercial Officer at Celltrion’s U.S. subsidiary, emphasized Zymfentra‘s improved administering convenience, enabling more flexible disease management for U.S. patients.
By Pulse
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]